Impact of gender on outcome after chemoimmunotherapy with fludarabine, cyclophosphamide and rituximab (FCR) or bendamustin plus R (BR) in CLL patients: a pooled analysis of the German CLL Study Group (GCLLSG)

被引：0

作者：

Al-Sawaf, O. ^{[1
]}

Kluth, S. ^{[1
]}

Bahlo, J. ^{[1
]}

Hopfinger, G. ^{[2
]}

Fink, A. M. ^{[1
]}

Cramer, P. ^{[1
]}

Maurer, C. ^{[1
]}

Bergmann, M. ^{[3
]}

Dreyling, M. ^{[4
]}

Lange, E. ^{[5
]}

Kneba, M. ^{[6
]}

Stilgenbauer, S. ^{[7
]}

Kiehl, M. G. ^{[8
]}

Jaeger, U. ^{[9
]}

Wendtner, C. M. ^{[3
]}

Fischer, K. ^{[1
]}

Hallek, M. ^{[1
,10
]}

Eichhorst, B. ^{[1
]}

机构：

[1] Uniklin Koln, Ctr Integrierte Onkol Koln Bonn, Klin Innere Med 1, Deutsch CLL Studiengrp, Cologne, Germany

[2] Med Univ Wien, Univ Klin Innere Med 1, Vienna, Austria

[3] Klinikum Munchen Schwabing, Klin Hamatol Onkol Immunol Palliat Med Infektiol, Munich, Germany

[4] Klinikum Univ Munchen, Med Klin & Poliklin 3, Munich, Germany

[5] Evangel Krankenhaus Hamm, Klin Hamatol Onkol & Palliat Med, Hamm, Germany

[6] Univ Klinikum Schleswig Holstein, Klin Hamatol Onkol & Palliat Med, Kiel, Germany

[7] Uniklin Ulm, Klin Innere Med 3, Ulm, Germany

[8] Klinikum Frankfurt Oder, Med Klin 1, Frankfurt, Oder, Germany

[9] Allgemeines Krankenhaus Wien, Klin Abt Hamatol & Hamostaseol, Vienna, Austria

[10] Uniklin Koln, CECAD Cluster Excellence Cellular Stress Response, Cologne, Germany

来源：

ONCOLOGY RESEARCH AND TREATMENT | 2016年 / 39卷

关键词：

D O I：

暂无

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

V685

引用

页码：212 / 213

页数：2

共 50 条

[1] Impact of Gender on Outcome after Chemoimmunotherapy with Fludarabine, Cyclophosphamide and Rituximab (FCR) or Bendamustine Plus Rituximab (BR) in Patients with Chronic Lymphocytic Leukemia (CLL): A Meta-Analysis of Three Phase II/III Studies of the German CLL Study Group (GCLLSG)
Al-Sawaf, Othman
Robrecht, Sandra
Bahlo, Jasmin
Fink, Anna Maria
Cramer, Paula
Maurer, Christian
Bergmann, Manuela A.
Dreyling, Martin H.
Lange, Elisabeth
Kneba, Michael
Stilgenbauer, Stephan
Dohner, Hartmut
Kiehl, Michael G.
Jager, Ulrich
Wendtner, Clemens-Martin
Fischer, Kirsten
Hallek, Michael
Eichhorst, Barbara F.
Hopfinger, Georg
BLOOD, 2016, 128 (22)
[2] Prediction of Poor Outcome in CLL Patients Treated with FCR (Fludarabine, Cyclophosphamide, Rituximab) in the CLL8 Trial of the German CLL Study Group (GCLLSG)
Fink, Anna
Busch, Raymonde
Pflug, Natali
Boettcher, Sebastian
Winkler, Dirk
Buehler, Andreas
Ritgen, Matthias
Fischer, Kirsten
Eichhorst, Barbara
Wendtner, Clemens-Martin
Mendila, Myriam
Wenger, Michael K.
Doehner, Hartmut
Kneba, Michael
Stilgenbauer, Stephan
Hallek, Michael
BLOOD, 2011, 118 (21) : 446 - 447
[3] More severe infectious complications in CLL patients treated with fludarabine, cyclophosphamide, rituximab (FCR) in comparison to bendamustin plus rituximab (BR): Results of the interim-analysis of the CLL10 trial of the German CLL Study Group
Langerbeins, P.
Busch, R.
Schweighofer, C. D.
Mueller, C.
Fischer, K.
Fink, A. -M.
Cramer, P.
Faetkenheuer, G.
Hartmann, P.
Stilgenbauer, S.
Boettcher, S.
Wendtner, C. -M.
Hallek, M.
Eichhorst, B.
ONCOLOGY RESEARCH AND TREATMENT, 2014, 37 : 185 - 185
[4] Fludarabine, cyclophosphamide and rituximab (FCR) first-line therapy in CLL patients: an analysis of the registry of the German CLL Study Group
Fink, A. M.
Federhen, A.
Kutsch, N.
Stumpf, J.
Giza, A.
Robrecht, S.
Stoltefuss, A.
Vehling-Kaiser, U.
Koenigsmann, M.
Tausch, E.
Schneider, C.
Stilgenbauer, S.
Illmer, T.
Schlag, R.
Doerfel, S.
Gaska, T.
Kiehl, M.
Fischer, K.
Eichhorst, B.
Hallek, M.
ONCOLOGY RESEARCH AND TREATMENT, 2022, 45 (SUPPL 2) : 119 - 120
[5] Fludarabine, Cyclophosphamide and Rituximab (FCR) As First Line Treatment in Patients with Chronic Lymphocytic Leukemia (CLL): A Long-Term Analysis of the German CLL Study Group (GCLLSG) Registry
Kutsch, Nadine
Fink, Anna Maria
Federhen, Anno
Giza, Adam
Robrecht, Sandra
Stumpf, Janina
Stoltefuss, Andrea
Vehling-Kaiser, Ursula
Koenigsmann, Michael
Tausch, Eugen
Schneider, Christof
Stilgenbauer, Stephan
Illmer, Thomas
Schlag, Rudolf
Doerfel, Steffen
Gaska, Tobias
Kiehl, Michael G.
Fischer, Kirsten
Eichhorst, Barbara
Hallek, Michael
BLOOD, 2022, 140 : 9879 - 9881
[6] Impact of gender on outcome after chemoimmunotherapy in patients with chronic lymphocytic leukemia: a meta-analysis of the German CLL Study Group (GCLLSG)
Al-Sawaf, Othman
Robrecht, Sandra
Bahlo, Jasmin
Fink, Anna-Maria
Cramer, Paula
Maurer, Christian
Bergmann, Manuela
Dreyling, Martin
Lange, Elisabeth
Kneba, Michael
Stilgenbauer, Stephan
Jaeger, Ulrich
Wendtner, Clemens
Fischer, Kirsten
Goede, Valentin
Hallek, Michael
Eichhorst, Barbara
Hopfinger, Georg
Doehner, Hartmut
Kiehl, Michael
LEUKEMIA & LYMPHOMA, 2017, 58 : 62 - 63
[7] Obesity Negatively Impacts Outcome in Female Patients with Chronic Lymphocytic Leukemia (CLL) Treated with Fludarabine, Cyclophosphamide and Rituximab (FCR): An Analysis of Three Phase III Studies of the German CLL Study Group (GCLLSG)
Fuerstenau, Moritz
Hopfinger, Georg
Robrecht, Sandra
Fink, Anna-Maria
Al-Sawaf, Othman
Langerbeins, Petra
Cramer, Paula
Von Tresckow, Julia
Maurer, Christian
Kutsch, Nadine
Hoechstetter, Manuela
Dreyling, Martin
Lange, Elisabeth
Kneba, Michael
Stilgenbauer, Stephan
Doehner, Hartmut
Hensel, Manfred
Kiehl, Michael G.
Jaeger, Ulrich
Wendtner, Clemens-Martin
Goede, Valentin
Fischer, Kirsten
Hallek, Michael
Eichhorst, Barbara
Theurich, Sebastian
BLOOD, 2018, 132
[8] Chemoimmunotherapy With Fludarabine (F), Cyclophosphamide (C), and Rituximab (R) (FCR) Versus Bendamustine and Rituximab (BR) In Previously Untreated and Physically Fit Patients (pts) With Advanced Chronic Lymphocytic Leukemia (CLL): Results Of a Planned Interim Trial, International, Randomized Study Of The German CLL Study Group (GCLLSG)
Eichhorst, Barbara
Fink, Anna-Maria
Busch, Raymonde
Lange, Elisabeth
Koeppler, Hubert
Kiehl, Michael
Soekler, Martin
Schlag, Rudolf
Vehling-Kaiser, Ursula
Koechling, Georg
Ploeger, Christoph
Gregor, Michael
Plesner, Torben
Trneny, Marek
Fischer, Kirsten
Doehner, Hartmut
Kneba, Michael
Wendtner, Clemens
Klapper, Wolfram
Kreuzer, Karl-Anton
Stilgenbauer, Stephan
Boettcher, Sebastian
Hallek, Michael
BLOOD, 2013, 122 (21)
[9] TP53 Mutations and Outcome After Fludarabine and Cyclophosphamide (FC) or FC Plus Rituximab (FCR) in the CLL8 Trial of the GCLLSG
Zenz, Thorsten
Hoth, Patrick
Busch, Raymonde
Helfrich, Hanne
Winkler, Dirk
Buehler, Andreas
Patten, Nancy
Truong, Sim
Wu, Lin
Fingerle-Rowson, Guenther
Fischer, Kirsten
Fink, Anna-Maria
Jaeger, Ulrich
Boettcher, Sebastian
Kneba, Michael
Wenger, Michael K.
Mendila, Myriam
Hallek, Michael
Doehner, Hartmut
Stilgenbauer, Stephan
BLOOD, 2009, 114 (22) : 521 - 521
[10] Favorable Toxicity Profile and Long Term Outcome of Elderly, but Physically Fit CLL Patients (pts) Receiving First Line Bendamustine and Rituximab (BR) Frontline Chemoimmunotherapy in Comparison to Fludarabine, Cyclophosphamide, and Rituximab (FCR) in Advanced Chronic Lymphocytic Leukemia (CLL): Update Analysis of an International, Randomized Study of the German CLL Study Group (GCLLSG) (CLL10 Study)
Eichhorst, Barbara F.
Bahlo, Jasmin
Maurer, Christian
Lange, Elisabeth
Koppler, Hubert
Kiehl, Michael G.
Sokler, Martin
Schlag, Rudolf
Vehling-Kaiser, Ursula
Kochling, Georg
Ploger, Christoph
Gregor, Michael
Plesner, Torben
Herling, Marco
Fischer, Kirsten
Dohner, Hartmut
Kneba, Michael
Wendtner, Clemens
Klapper, Wolfram
Kreuzer, Karl-Anton
Bottcher, Sebastian
Stilgenbauer, Stephan
Fink, Anna Maria
Hallek, Michael
BLOOD, 2016, 128 (22)

← 1 2 3 4 5 →